Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors
J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, explains the potential to combine letrozole with targeted therapies.
Dixon cites a neoadjuvant trial that examined the mTOR inhibitor RAD001 (everolimus) plus letrozole. This trial showed benefit, but with too much toxicity. This trial showed it was possible to combine letrozole with targeted agents. This will lead to further investigation in the future.